Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Long-Term Debt of $4.67 million for fiscal year 2024.
Tonix Pharmaceuticals Holding Corp. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $4.67M | -28.9% |
| 2023 | $6.56M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| December 31, 2024 | $4.67M | -28.9% | -9.8% |
| September 30, 2024 | $5.17M | — | -8.8% |
| June 30, 2024 | $5.67M | — | -8.0% |
| March 31, 2024 | $6.16M | — | -6.1% |
| December 31, 2023 | $6.56M | — | — |
- Tonix Pharmaceuticals Holding Corp. showed a decrease of -28.9% in Long-Term Debt compared to the prior fiscal year.
- Over the 2023–2024 period, Tonix Pharmaceuticals Holding Corp.’s long-term debt has declined by 28.9% (from $6.56 million to $4.67 million).
- The most recent figure is from Tonix Pharmaceuticals Holding Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: